Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25875125 | 0.89 | KDM4E (0.34) | — | |
| SCHEMBL26311013 | 0.77 | ATM (0.39) | PKMSMN1; SMN2CYP1A2 | |
| SCHEMBL9973365 | 0.77 | SMN1; SMN2 (0.40) | PKMSMN1; SMN2 | |
| SCHEMBL25875132 | 0.75 | CYP1A2 (0.35) | PKMSMN1; SMN2CYP1A2 | |
| SCHEMBL13255492 | 0.75 | USP2 (0.37) | CYP1A2 | |
| SCHEMBL25875079 | 0.71 | ALDH1A1 (0.33) | SMN1; SMN2 | |
| SCHEMBL26311011 | 0.70 | MGLL (0.31) | CYP1A2 | |
| SCHEMBL20013169 | 0.69 | APP (0.35) | — | |
| SCHEMBL19105220 | 0.68 | PKM (0.37) | PKMSMN1; SMN2 | |
| SCHEMBL19105450 | 0.67 | PKM (0.38) | PKMSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212209-A1 | COMPOSITIONS AND METHODS FOR LIQUID PHASE OLIGONUCLEOTIDE SYNTHESIS | HONGENE BIOTECH CORPORATION | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212209-A1 | COMPOSITIONS AND METHODS FOR LIQUID PHASE OLIGONUCLEOTIDE SYNTHESIS | POLR2H, POLR2E, POLI | PKM 3120/4885SMN1; SMN2 1972/4885CYP1A2 4875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.